CTOs on the Move

89bio

www.89bio.com

 
We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.89bio.com
  • 535 Mission Street 14th Floor
    San Francisco, CA USA 94105
  • Phone: 212.520.2765

Executives

Name Title Contact Details

Funding

89bio raised $60M on 10/25/2018
89bio raised $83.8M on 07/14/2020

Similar Companies

Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets.

Cogenix

Cogenix is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

THEON Therapeutics

THEON is a patient-focused drug discovery company developing small molecule correctors of RNA pathobiology.

Abcuro

Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1).